UK markets closed

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
9.36+0.25 (+2.74%)
At close: 04:00PM EDT
9.12 -0.24 (-2.56%)
After hours: 06:13PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 489.44M
Enterprise value 334.75M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)9.78
Price/book (mrq)2.39
Enterprise value/revenue 6.85
Enterprise value/EBITDA -5.01

Trading information

Stock price history

Beta (5Y monthly) 0.93
52-week change 3-40.26%
S&P500 52-week change 3-16.45%
52-week high 318.93
52-week low 37.40
50-day moving average 310.24
200-day moving average 310.53

Share statistics

Avg vol (3-month) 3415.42k
Avg vol (10-day) 3450.26k
Shares outstanding 553.73M
Implied shares outstanding 6N/A
Float 845.12M
% held by insiders 116.18%
% held by institutions 167.09%
Shares short (30 Aug 2022) 47.13M
Short ratio (30 Aug 2022) 415.84
Short % of float (30 Aug 2022) 418.80%
Short % of shares outstanding (30 Aug 2022) 413.27%
Shares short (prior month 28 Jul 2022) 47.24M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022


Profit margin -135.72%
Operating margin (ttm)-137.11%

Management effectiveness

Return on assets (ttm)-18.70%
Return on equity (ttm)-32.53%

Income statement

Revenue (ttm)48.89M
Revenue per share (ttm)0.93
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)-59.67M
EBITDA -66.78M
Net income avi to common (ttm)-66.35M
Diluted EPS (ttm)-1.80
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)157.51M
Total cash per share (mrq)2.93
Total debt (mrq)2.82M
Total debt/equity (mrq)1.38
Current ratio (mrq)8.32
Book value per share (mrq)3.81

Cash flow statement

Operating cash flow (ttm)-45.39M
Levered free cash flow (ttm)-20.34M